Schering-Plough Gets 2 Subpoenas

Schering-Plough Corp. received two subpoenas this month from the U.S. attorney’s office in Massachusetts in a criminal investigation of the drug maker’s sales and marketing practices. The probe relates to Intron A, Rebetron and Temodar drug sales and marketing to managed-care organizations and doctors, the company said in a statement.

Schering-Plough is among several U.S. drug companies being investigated for industry pricing practices. The company previously disclosed that it was under investigation by federal officials in Boston on whether drug prices were inflated.